GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perrigo Co PLC (NYSE:PRGO) » Definitions » EV-to-EBIT

Perrigo Co (Perrigo Co) EV-to-EBIT

: 44.58 (As of Today)
View and export this data going back to 1991. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Perrigo Co's Enterprise Value is $7,382 Mil. Perrigo Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $166 Mil. Therefore, Perrigo Co's EV-to-EBIT for today is 44.58.

The historical rank and industry rank for Perrigo Co's EV-to-EBIT or its related term are showing as below:

PRGO' s EV-to-EBIT Range Over the Past 10 Years
Min: -127.35   Med: 38.69   Max: 516.53
Current: 44.58

During the past 13 years, the highest EV-to-EBIT of Perrigo Co was 516.53. The lowest was -127.35. And the median was 38.69.

PRGO's EV-to-EBIT is ranked worse than
86.38% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.04 vs PRGO: 44.58

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Perrigo Co's Enterprise Value for the quarter that ended in Dec. 2023 was $7,683 Mil. Perrigo Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $166 Mil. Perrigo Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.16%.


Perrigo Co EV-to-EBIT Historical Data

The historical data trend for Perrigo Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perrigo Co Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.84 67.71 18.33 479.16 46.42

Perrigo Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 479.16 203.96 46.56 39.21 46.42

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perrigo Co EV-to-EBIT Distribution

For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Perrigo Co's EV-to-EBIT falls into.



Perrigo Co EV-to-EBIT Calculation

Perrigo Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=7382.158/165.6
=44.58

Perrigo Co's current Enterprise Value is $7,382 Mil.
Perrigo Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $166 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perrigo Co  (NYSE:PRGO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Perrigo Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=165.6/7682.68308
=2.16 %

Perrigo Co's Enterprise Value for the quarter that ended in Dec. 2023 was $7,683 Mil.
Perrigo Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $166 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perrigo Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Perrigo Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Perrigo Co (Perrigo Co) Business Description

Traded in Other Exchanges
Address
The Sharp Building, Hogan Place, Dublin, IRL, D02 TY74
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Executives
Robert Willis officer: Acting CHRO C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Alison Ives officer: EVP & Chief Scientific Officer C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Eduardo Guarita Bezerra officer: EVP & Chief Financial Officer C/O FRESH DEL MONTE PRODUCE INC., PO BOX 149222, CORAL GABLES FL 33134
Patrick Lockwood-taylor director, officer: CEO C/O PERRIGO COMPANY PLC, 430 MONROE AVE NW, GRAND RAPIDS MI 49503
Julia M Brown director C/O ABLE BRANDS CO., 30 HUDSON YARDS, NEW YORK NY 10001
Triona Schmelter officer: EVP & President CSCA 2021 SPRING ROAD, SUITE 600, OAK BROOK IL 60523
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Svend Andersen director C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Murray S Kessler director, officer: CEO 714 GREEN VALLEY ROAD, GREENSBORO NC 27408
Thomas Farrington officer: Senior VP and CIO 4012 W. CANTERBURY CT., NEQUON WI 53092
Dillard James E Iii officer: EVP, Chief Scientific Officer 6601 WEST BROAD STREET, RICHMOND VA 23230
Ronald Craig Janish officer: EVP, Global Op. & Supply Chain PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Grainne Quinn officer: EVP, Chief Medical Officer PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Albert Manzone director C/O MERISANT, AVENUE JEAN-JACQUES ROUSSEAU 7, NEUCHATEL V8 CH-2000
Kyle Hanson officer: EVP & General Counsel